Related Experiment Video
Updated: Jul 17, 2025

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
What the X? Understanding changes in buprenorphine prescribing regulation
1Department of Advanced Nursing Practice and Education, College of Nursing, East Carolina University, Greenville, North Carolina.
Abstract:
Opioid use disorder remains an epidemic in the United States. Buprenorphine is a Food and Drug Administration-approved medication for opioid use disorder that is associated with decreased opioid-related mortality and morbidity. Until recently, providers had to have a specialized wavier, a Drug Enforcement Agency (DEA) X, to prescribe buprenorphine for opioid use disorder. The 2023 Consolidated Appropriations Act, signed into law by President Biden, removed X waiver requirements and implements new training requirements for all new and renewing DEA registrants. This brief report outlines the history of buprenorphine prescribing regulation, reviews the recent regulatory changes and their implications for nurse practitioner buprenorphine prescribing, and concludes by considering the importance of promoting buprenorphine access.
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Opioid Receptors: Overview

